ALVR

AlloVir, Inc.

0.77 USD
+0.02 (+2.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AlloVir, Inc. stock is down -4.46% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 10 May’s closed higher than April.

About AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. The company's lead product is posoleucel, which is an allogenic off the shelf VST therapy. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19.